Washington Univ School of Medicine .
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nakano, Taizo
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Active, not recruiting
3
194
Europe, Canada, Japan, US, RoW
Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo
Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.
Immune Thrombocytopenia
06/25
11/26
PINES, NCT03939637: Eltrombopag Vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Active, not recruiting
3
122
US
Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin
Baylor College of Medicine, Boston Children's Hospital, University of California, San Francisco
Immune Thrombocytopenia
03/25
12/25
TransIT, NCT05600426: A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (, BMT CTN 2202)

Recruiting
3
234
Canada, US
cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), ATGAM, rabbit anti-thymocyte globulin (ATG), thymoglobulin, Methotrexate, Fludarabine, Cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST)
Boston Children's Hospital, Center for International Blood and Marrow Transplant Research, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), North American Pediatric Aplastic Anemia Consortium, Pediatric Transplantation and Cellular Therapy Consortium, Blood and Marrow Transplant Clinical Trials Network
Severe Aplastic Anemia
12/29
12/29
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31
ITP-APPS, NCT03810352: Association of Platelet Parameters With Bleeding Severity in Children With ITP

Completed
N/A
95
US
Boston Children's Hospital, Sysmex America, Inc., Children's Hospital Colorado, Children's Hospital of Philadelphia, Baylor College of Medicine, Columbia University, Duke University
Immune Thrombocytopenia
11/23
11/23
SDSR, NCT06056908: Shwachman Diamond Syndrome Registry and Study

Recruiting
N/A
5000
US
Boston Children's Hospital, Children's Hospital Medical Center, Cincinnati
Shwachman-Diamond Syndrome, Shwachman-Diamond Syndrome-Like
01/90
01/90
Schulz, Yvette
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31

Download Options